Amgen, Inc. (AMGN) Stock Price Today
Key Stats
- $222.32BMarket Cap
- -Volume
- HealthSector
- $410.9552W High
- $271.1852W Low
- -Typical Hold Time
- $265.64BEnterprise Value
- 2.45%Div Yield
- -Trading Activity
Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $415.7, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
Hims & Hers misses Q2 EPS but beats revenue estimates, raises full-year revenue forecast.
Hims & Hers Health, Inc. reported a second-quarter 2026 earnings per share (EPS) loss of $0.10, missing the expected loss of $0.05. However, the company exceeded revenue expectations with $753.21 million, above the $698.89 million estimate, driven by...
Stocks of INNOVATE Corp. and Bitdeer Technologies plunge over 20% despite positive earnings reports.
Several companies including INNOVATE Corp., Lincoln Educational, and Bitdeer Technologies saw their stock prices drop by more than 20% despite reporting strong revenue growth and positive operational results. INNOVATE Corp. led the decline with a 39....
Stocks surge on major acquisition deals and strong Q2 results for Aligos Therapeutics
Shares of Bowman Consulting, Varex Imaging, and MarineMax jumped significantly after each announced all-cash acquisition agreements valued between $1 billion and $1.5 billion. Bowman Consulting agreed to be acquired by Bernhard Capital Partners for $...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.